Login
Companies $TARA
$2.42 +$0.04 (1.68%) After hours
Protara Therapeutics, Inc. logo

Protara Therapeutics, Inc.

protaratx.com

What Do They Do?

Develops an investigational cell therapy for bladder cancer and lymphatic malformations, plus an intravenous choline treatment for patients receiving nutrition and fluids through a vein.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −64% (Loss)
vs −$13.3M in Q3 FY2025

Broader choline-treatment use The earlier report described choline treatment for people receiving parenteral nutrition who had intestinal failure-associated liver disease. The latest report describes it as a choline source when nutrition by mouth or through the digestive tract cannot be used, is inadequate, or is contraindicated.

Who Do They Compete With?

Competes with Merck &, Endo International, Ferring, ImmunityBio, Janssen, Japanese BCG Laboratory, Pfizer, CG Oncology, enGene, Urogen Pharma, Theralase Technologies, Auro BioSciences, Verity, AstraZeneca, Bristol-Myers Squibb, Roche Group, Asieris Pharmaceuticals, BeiGene, NanOlogy, and Linton Pharm

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support